Investors

PTC Therapeutics, Inc. is committed to serving the interests of our shareholders. This part of our website includes corporate governance documents, press releases, financial information and other documents to help shareholders better understand who we are and what we do.

Press Releases

Jun 22, 2017

New Analyses of Translarna™ (ataluren) Data from ACT DMD Presented at the 12th Annual European Pediatric Neurology Society Congress

Jun 6, 2017

PTC Therapeutics Announces FDA Advisory Committee Meeting for Ataluren for the Treatment of Nonsense Mutation Dystrophinopathy

View all press releases »

Events & Presentations

Mar 2, 2017 at 9:00 AM

PTC Call To Discuss ACT CF Results

View all events & presentations »

NASDAQ: PTCT

18.39

0.00 (0.00%)

4:00 PM ET on Jun 26, 2017

Delayed at least 20 minutes.

Intra
3 mo.
6 mo.
1 yr.

Intraday stock price graph

3 month stock price graph

6 month stock price graph

12 month stock price graph

Events & Presentations

Corporate Governance

Financial Information

Annual Report and Proxy

Stock Information

Shareholder Tools

Printed Materials

Email Alerts

RSS

You are now leaving this website. If you would like to continue, click Continue.

Cancel Continue